SCHEMBL7017277

SCHEMBL7017277

CCCCC(C)[S+]([O-])C(C)CCCC.c1cc(-c2ccc3c(c2)ncn3-c2ccncn2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 3/20 0.46
AAK1 Q2M2I8 5/20 0.34
PLK1 P53350 2/20 0.34
PLK3 Q9H4B4 2/20 0.34
CYP2C9 P11712 1/20 0.34
KDR P35968 1/20 0.33
FGFR1 P11362 1/20 0.33
CYP1A2 P05177 1/20 0.33
PDE10A Q9Y233 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
RPS6KA5 O75582 1/20 0.32
CYP17A1 P05093 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
HTR6 P50406 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7019434 0.69 LCK (0.49) LCKAAK1KDRFGFR1CYP3A4
SCHEMBL7027218 0.67 LCK (0.48) LCKAAK1PLK1PLK3CYP2C9
SCHEMBL7498487 0.65 LCK (0.57) LCKPLK1PLK3CYP2C9KDR
SCHEMBL7497256 0.63 LCK (0.55) LCKPLK1PLK3CYP2C9KDR
SCHEMBL7677283 0.63 KDR (0.68) LCKCYP2C9KDRFGFR1CYP1A2
SCHEMBL7592779 0.63 LCK (1.00) LCKMKNK1MKNK2
SCHEMBL7016875 0.63 LCK (1.00) LCKMKNK1MKNK2
SCHEMBL15551598 0.62 POLB (0.67) LCKFGFR1CYP1A2PDE10ARPS6KA5
SCHEMBL3153061 0.60 LCK (0.71) LCKKDRFGFR1
Lithium Ion SCHEMBL17315061 0.60 KDR (0.49) LCKCYP2C9KDRFGFR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP disclosed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed